In a major development for obesity treatment, Novo Nordisk’s Wegovy (semaglutide) is now available as a once-daily oral pill in the United States. The U.S. Food and Drug Administration (FDA) approved the tablet version on December 22, 2025, marking it as the first oral GLP-1 receptor agonist specifically approved for chronic weight management in adults with obesity or overweight (with at least one weight-related condition). The pill launched broadly across pharmacies and other channels starting January 5, 2026.
Both the new oral Wegovy and the original once-weekly injection share the same active ingredient, semaglutide, which mimics the GLP-1 hormone to suppress appetite, slow gastric emptying, and support sustained weight loss. They are also approved to reduce the risk of major cardiovascular events, such as heart attack or stroke, in eligible patients with established heart disease.
Similarities Between the Pill and Injection
- Efficacy: Clinical trials demonstrate comparable weight loss when patients adhere fully to treatment. The injectable Wegovy (up to 2.4 mg weekly) achieved an average weight loss of about 15% over 68 weeks in key studies. The oral pill (up to 25 mg daily) delivered around 16.6% mean weight loss at 64 weeks with full adherence in the OASIS 4 trial (or about 13.6-14% in broader analyses including those who discontinued). Real-world results may vary based on lifestyle factors like diet and exercise.
- Side Effects: Both forms primarily cause gastrointestinal issues, such as nausea, vomiting, diarrhea, and constipation. These are typically dose-dependent and often improve over time. A boxed warning applies to both regarding the potential risk of thyroid C-cell tumors (based on rodent studies).
- Purpose: Used alongside reduced-calorie diet and increased physical activity for long-term weight management and cardiometabolic benefits.
Key Differences: Pill vs. Injection
The two formulations differ significantly in how they are taken, absorbed, and managed day-to-day.
- Administration:
- Pill: Taken once daily in the morning on an empty stomach with a sip of water. Patients must wait at least 30 minutes before eating, drinking anything else, or taking other oral medications to ensure proper absorption (only a small fraction is bioavailable due to digestion).
- Injection: Administered once weekly via subcutaneous injection (in the thigh, abdomen, or upper arm), with no strict timing relative to meals.
- Dosing and Titration:
- Pill: Starts at 1.5 mg daily, with gradual increases (e.g., every 4 weeks) up to a maintenance dose of 25 mg.
- Injection: Begins at 0.25 mg weekly, titrating up to 2.4 mg.
- Absorption and Predictability:
- Pill: Lower and more variable bioavailability, making strict adherence to instructions critical. Real-world adherence may be challenging due to the daily routine and restrictions.
- Injection: Provides more consistent, direct absorption with fewer daily variables.
- Convenience and Practicality:
- Pill: Needle-free, no refrigeration required, and easier storage—appealing to those averse to injections.
- Injection: Weekly dosing may be simpler for some, though it involves self-injecting.
- Cost (Approximate Self-Pay as of January 2026):
- Pill: Starter doses (1.5 mg and initially 4 mg) at $149 per month (promotional pricing through April 15, 2026, for the 4 mg dose), with higher doses up to $299 per month.
- Injection: Around $349 per month (with introductory offers like $199 for initial doses).
- Insurance coverage or Novo Nordisk savings programs can reduce costs significantly (potentially to $25/month for eligible patients on either form).
Which Option Might Suit You Better?
The choice between the oral pill and injection ultimately depends on personal preferences and lifestyle:
- Opt for the pill if you dislike needles, prefer daily routines, and can reliably follow the strict morning instructions.
- Choose the injection if you want fewer doses, more predictable results, or find weekly administration easier to maintain long-term.
Neither form is a magic solution—success requires ongoing commitment to healthy habits and medical oversight. Demand for Wegovy remains high, so check with pharmacies, telehealth providers, or Novo Nordisk’s NovoCare program for availability. Always consult a healthcare provider to determine eligibility, discuss potential risks (including contraindications like personal/family history of medullary thyroid carcinoma), and monitor progress. This oral breakthrough expands options in the evolving landscape of obesity care, offering more people a convenient path to meaningful weight loss.
About The Author
